Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab

P. Mohr, P. Ascierto, A. Arance, G. McArthur, A. Hernaez, P. Kaskel, R. Shinde, K. Stevinson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: There is a scarcity of real-world data on treatment patterns and outcomes among advanced melanoma patients treated with immunotherapies including ipilimumab, an anti-CTLA-4 antibody approved since 2011. Objective: To evaluate ipilimumab and postipilimumab treatment patterns and outcomes among patients with advanced melanoma in Australia, Germany, Italy and Spain, following regulatory approval. Methods: Retrospective multicentre, multinational, observational chart review study. Data were extracted from the start of ipilimumab therapy until the end of at least 40 weeks of follow-up, or death. Results: Data from 371 patients (Australia, 103; Germany, 152; Italy, 76; Spain, 40) were analysed. Mean age was 65 years; 62% were male. Eastern Cooperative Oncology Group performance status (ECOG PS) was 0 or 1 for 94%. In 67%, ipilimumab was initially received as second-line or later therapy. Patients received on average 3.4 ipilimumab doses. The ipilimumab-refractory cohort comprised of 226 patients. Of these, 17% in Australia, 47% in Germany, 29% in Italy and 14% in Spain received another antimelanoma treatment after ipilimumab including chemotherapy in 26% and BRAF/other kinase inhibitors in 11%. Ipilimumab-refractory patients who received postipilimumab treatment showed a 40% reduced hazard of dying than those not receiving treatment after ipilimumab (HR 0.60; 95% CI 0.43–0.83), after adjustment for potential confounders. Conclusion: During the time observed, ipilimumab was mainly used as second-line or later therapy. A significant proportion of patients received postipilimumab therapy, most of which was chemotherapy. Nevertheless, overall survival following progression on ipilimumab treatment remained poor, highlighting the need for research to develop more effective end-of-life treatment options.

Original languageEnglish
Pages (from-to)962-971
Number of pages10
JournalJournal of the European Academy of Dermatology and Venereology
Volume32
Issue number6
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Melanoma
Skin
Spain
Italy
Germany
Therapeutics
Proto-Oncogene Proteins B-raf
ipilimumab
Drug Therapy
Immunotherapy
Survival
Antibodies
Research

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab. / Mohr, P.; Ascierto, P.; Arance, A.; McArthur, G.; Hernaez, A.; Kaskel, P.; Shinde, R.; Stevinson, K.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 32, No. 6, 01.06.2018, p. 962-971.

Research output: Contribution to journalArticle

Mohr, P. ; Ascierto, P. ; Arance, A. ; McArthur, G. ; Hernaez, A. ; Kaskel, P. ; Shinde, R. ; Stevinson, K. / Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab. In: Journal of the European Academy of Dermatology and Venereology. 2018 ; Vol. 32, No. 6. pp. 962-971.
@article{80f57c23def943588f109c1e12830598,
title = "Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab",
abstract = "Background: There is a scarcity of real-world data on treatment patterns and outcomes among advanced melanoma patients treated with immunotherapies including ipilimumab, an anti-CTLA-4 antibody approved since 2011. Objective: To evaluate ipilimumab and postipilimumab treatment patterns and outcomes among patients with advanced melanoma in Australia, Germany, Italy and Spain, following regulatory approval. Methods: Retrospective multicentre, multinational, observational chart review study. Data were extracted from the start of ipilimumab therapy until the end of at least 40 weeks of follow-up, or death. Results: Data from 371 patients (Australia, 103; Germany, 152; Italy, 76; Spain, 40) were analysed. Mean age was 65 years; 62{\%} were male. Eastern Cooperative Oncology Group performance status (ECOG PS) was 0 or 1 for 94{\%}. In 67{\%}, ipilimumab was initially received as second-line or later therapy. Patients received on average 3.4 ipilimumab doses. The ipilimumab-refractory cohort comprised of 226 patients. Of these, 17{\%} in Australia, 47{\%} in Germany, 29{\%} in Italy and 14{\%} in Spain received another antimelanoma treatment after ipilimumab including chemotherapy in 26{\%} and BRAF/other kinase inhibitors in 11{\%}. Ipilimumab-refractory patients who received postipilimumab treatment showed a 40{\%} reduced hazard of dying than those not receiving treatment after ipilimumab (HR 0.60; 95{\%} CI 0.43–0.83), after adjustment for potential confounders. Conclusion: During the time observed, ipilimumab was mainly used as second-line or later therapy. A significant proportion of patients received postipilimumab therapy, most of which was chemotherapy. Nevertheless, overall survival following progression on ipilimumab treatment remained poor, highlighting the need for research to develop more effective end-of-life treatment options.",
author = "P. Mohr and P. Ascierto and A. Arance and G. McArthur and A. Hernaez and P. Kaskel and R. Shinde and K. Stevinson",
year = "2018",
month = "6",
day = "1",
doi = "10.1111/jdv.14633",
language = "English",
volume = "32",
pages = "962--971",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "wiley",
number = "6",

}

TY - JOUR

T1 - Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab

AU - Mohr, P.

AU - Ascierto, P.

AU - Arance, A.

AU - McArthur, G.

AU - Hernaez, A.

AU - Kaskel, P.

AU - Shinde, R.

AU - Stevinson, K.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: There is a scarcity of real-world data on treatment patterns and outcomes among advanced melanoma patients treated with immunotherapies including ipilimumab, an anti-CTLA-4 antibody approved since 2011. Objective: To evaluate ipilimumab and postipilimumab treatment patterns and outcomes among patients with advanced melanoma in Australia, Germany, Italy and Spain, following regulatory approval. Methods: Retrospective multicentre, multinational, observational chart review study. Data were extracted from the start of ipilimumab therapy until the end of at least 40 weeks of follow-up, or death. Results: Data from 371 patients (Australia, 103; Germany, 152; Italy, 76; Spain, 40) were analysed. Mean age was 65 years; 62% were male. Eastern Cooperative Oncology Group performance status (ECOG PS) was 0 or 1 for 94%. In 67%, ipilimumab was initially received as second-line or later therapy. Patients received on average 3.4 ipilimumab doses. The ipilimumab-refractory cohort comprised of 226 patients. Of these, 17% in Australia, 47% in Germany, 29% in Italy and 14% in Spain received another antimelanoma treatment after ipilimumab including chemotherapy in 26% and BRAF/other kinase inhibitors in 11%. Ipilimumab-refractory patients who received postipilimumab treatment showed a 40% reduced hazard of dying than those not receiving treatment after ipilimumab (HR 0.60; 95% CI 0.43–0.83), after adjustment for potential confounders. Conclusion: During the time observed, ipilimumab was mainly used as second-line or later therapy. A significant proportion of patients received postipilimumab therapy, most of which was chemotherapy. Nevertheless, overall survival following progression on ipilimumab treatment remained poor, highlighting the need for research to develop more effective end-of-life treatment options.

AB - Background: There is a scarcity of real-world data on treatment patterns and outcomes among advanced melanoma patients treated with immunotherapies including ipilimumab, an anti-CTLA-4 antibody approved since 2011. Objective: To evaluate ipilimumab and postipilimumab treatment patterns and outcomes among patients with advanced melanoma in Australia, Germany, Italy and Spain, following regulatory approval. Methods: Retrospective multicentre, multinational, observational chart review study. Data were extracted from the start of ipilimumab therapy until the end of at least 40 weeks of follow-up, or death. Results: Data from 371 patients (Australia, 103; Germany, 152; Italy, 76; Spain, 40) were analysed. Mean age was 65 years; 62% were male. Eastern Cooperative Oncology Group performance status (ECOG PS) was 0 or 1 for 94%. In 67%, ipilimumab was initially received as second-line or later therapy. Patients received on average 3.4 ipilimumab doses. The ipilimumab-refractory cohort comprised of 226 patients. Of these, 17% in Australia, 47% in Germany, 29% in Italy and 14% in Spain received another antimelanoma treatment after ipilimumab including chemotherapy in 26% and BRAF/other kinase inhibitors in 11%. Ipilimumab-refractory patients who received postipilimumab treatment showed a 40% reduced hazard of dying than those not receiving treatment after ipilimumab (HR 0.60; 95% CI 0.43–0.83), after adjustment for potential confounders. Conclusion: During the time observed, ipilimumab was mainly used as second-line or later therapy. A significant proportion of patients received postipilimumab therapy, most of which was chemotherapy. Nevertheless, overall survival following progression on ipilimumab treatment remained poor, highlighting the need for research to develop more effective end-of-life treatment options.

UR - http://www.scopus.com/inward/record.url?scp=85033599122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033599122&partnerID=8YFLogxK

U2 - 10.1111/jdv.14633

DO - 10.1111/jdv.14633

M3 - Article

VL - 32

SP - 962

EP - 971

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 6

ER -